TherapeuticsMD Inc (NASDAQ:TXMD) Receives Consensus Rating of “Buy” from Analysts

Shares of TherapeuticsMD Inc (NASDAQ:TXMD) have been given an average recommendation of “Buy” by the thirteen analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $9.60.

A number of equities analysts have recently commented on TXMD shares. Oppenheimer set a $9.00 target price on shares of TherapeuticsMD and gave the company a “buy” rating in a research note on Thursday, August 22nd. Guggenheim started coverage on shares of TherapeuticsMD in a research note on Monday. They issued a “buy” rating and a $5.00 target price on the stock. Noble Financial reissued a “buy” rating and issued a $13.00 target price on shares of TherapeuticsMD in a research note on Friday, September 27th. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of TherapeuticsMD in a research note on Tuesday, October 29th. Finally, BidaskClub downgraded shares of TherapeuticsMD from a “sell” rating to a “strong sell” rating in a research note on Thursday, November 28th.

Shares of TXMD stock opened at $2.42 on Tuesday. The company’s fifty day simple moving average is $2.95 and its 200-day simple moving average is $2.93. TherapeuticsMD has a 52 week low of $1.82 and a 52 week high of $6.09. The company has a current ratio of 2.85, a quick ratio of 2.69 and a debt-to-equity ratio of 24.29. The company has a market cap of $656.25 million, a PE ratio of -4.10 and a beta of 1.66.

TherapeuticsMD (NASDAQ:TXMD) last issued its earnings results on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.06. TherapeuticsMD had a negative net margin of 427.70% and a negative return on equity of 430.28%. The business had revenue of $8.21 million for the quarter, compared to the consensus estimate of $8.05 million. During the same quarter last year, the firm posted ($0.16) EPS. The business’s revenue for the quarter was up 136.6% compared to the same quarter last year. Equities research analysts expect that TherapeuticsMD will post -0.69 EPS for the current fiscal year.

In other news, insider John C.K. Iv Milligan purchased 72,000 shares of the stock in a transaction that occurred on Friday, October 25th. The stock was acquired at an average cost of $2.75 per share, with a total value of $198,000.00. Following the acquisition, the insider now owns 1,544,419 shares in the company, valued at $4,247,152.25. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Group L. P. Column purchased 4,387 shares of the stock in a transaction that occurred on Wednesday, October 23rd. The shares were purchased at an average cost of $12.66 per share, with a total value of $55,539.42. Over the last ninety days, insiders have purchased 112,387 shares of company stock valued at $352,539. Company insiders own 18.91% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC grew its holdings in TherapeuticsMD by 470.5% during the 2nd quarter. SG Americas Securities LLC now owns 2,804,571 shares of the company’s stock worth $7,292,000 after acquiring an additional 2,312,933 shares in the last quarter. Moloney Securities Asset Management LLC acquired a new position in TherapeuticsMD during the 2nd quarter worth $27,000. Aperio Group LLC grew its holdings in TherapeuticsMD by 87.0% during the 2nd quarter. Aperio Group LLC now owns 29,593 shares of the company’s stock worth $77,000 after acquiring an additional 13,771 shares in the last quarter. Advisor Group Inc. grew its holdings in TherapeuticsMD by 73.2% during the 2nd quarter. Advisor Group Inc. now owns 13,960 shares of the company’s stock worth $36,000 after acquiring an additional 5,900 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado grew its holdings in TherapeuticsMD by 12.7% during the 2nd quarter. Public Employees Retirement Association of Colorado now owns 1,632,233 shares of the company’s stock worth $4,244,000 after acquiring an additional 183,533 shares in the last quarter. 63.63% of the stock is owned by institutional investors and hedge funds.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Recommended Story: What is the yield curve?

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.